The buyout price* of $28.35/sh in cash is a 498%* premium to TBRA’s closing price yesterday. The 498% premium is the largest I've ever seen in a biotech deal (see next post). The nominal deal value* is $615M.
*Excluding CVR potentially worth $49.84/sh.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.